Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.
A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine
Dold C. et al, (2025), Science Translational Medicine, 17
Acceptability of the R21/Matrix-M malaria vaccine alongside existing malaria interventions in the trial context.
Diawara H. et al, (2025), BMJ global health, 10
Altered IL-6 signalling and risk of tuberculosis: a multi-ancestry mendelian randomisation study
Hamilton F. et al, (2025), The Lancet Microbe, 6, 100922 - 100922
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Venkatraman N. et al, (2025), The Lancet Microbe, 100868 - 100868
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection study.
Venkatraman N. et al, (2025), The Lancet. Microbe
The R21/Matrix-M malaria vaccine: questions remain - Author's reply.
Datoo MS. et al, (2025), Lancet (London, England), 405, 299 - 301
Validation of a multiplexed immunoassay for immunological analysis of pre erythrocytic malaria vaccines.
Stockdale LK. et al, (2025), NPJ vaccines, 10
A comparative immunological assessment of multiple clinical-stage adjuvants for the R21 malaria vaccine in nonhuman primates.
Arunachalam PS. et al, (2024), Sci Transl Med, 16
A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.
Hanboonkunupakarn B. et al, (2024), NPJ vaccines, 9
High-resolution African HLA resource uncovers HLA-DRB1 expression effects underlying vaccine response
Mentzer AJ. et al, (2024), Nature Medicine, 30, 1384 - 1394
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study.
Schmit N. et al, (2024), The Lancet. Infectious diseases, 24, 465 - 475
Chemical and biological characterization of vaccine adjuvant QS-21 produced via plant cell culture
Lv X. et al, (2024), iScience, 27
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
Datoo MS. et al, (2024), The Lancet, 403, 533 - 544
Multi-ancestry meta-analysis of host genetic susceptibility to tuberculosis identifies shared genetic architecture
Schurz H. et al, (2024), eLife, 13
A common NFKB1 variant detected through antibody analysis in UK Biobank predicts risk of infection and allergy.
Chong AY. et al, (2024), American journal of human genetics
Mexican Biobank advances population and medical genomics of diverse ancestries.
Sohail M. et al, (2023), Nature